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Cyclosporine (Cy A) is now considered a primary 
immunosuppressant used to prevent organ rejec-
tion in liver, kidney, and heart transplant patients 
(1-3). It has been recommended that the blood 
level of Cy A be monitored in these patients to min-
imize the possibility of rejection due to low CyA 
blood concentrations or potential toxicity due to 
high CyA concentrations (4,5). This is based on the 
observation of marked variations in the trough Cy A 
blood levels between and within patients. Such 
variations in blood levels are the result of pro-
nounced differences in the pharmacokinetic param-
eters, such as clearance and bioavailability (6-8). 
We report on one factor, diurnal variation, that may 
contribute to the observed variability in the phar-
macokinetics of Cy A in transplant patients. 
Cy A pharmacokinetics were studied during two 
or three different dosing intervals (8 h) in two pa-
tients who underwent orthotopic liver transplanta-
tion at the University of Pittsburgh. The same 
maintenance dose of CyA (patient 1, 140 mg; pa-
tient 2, 150 mg) was administered over 1 h as an 
intravenous infusion in the morning and at night. 
Hourly blood samples were drawn and analyzed for 
cycIosporine following modifications of a high 
pressure liquid chromatographic assay (9). Kinetic 
parameters were calculated according to standard 
techniques (10). 
The biochemical profiles on different study pe-
riods in a given patient were similar. 
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Table 1 summarizes the pharmacokinetic param-
eters obtained. The 8-h trough levels (Cmin) ob-
tained following drug administration at night were 
lower than the trough levels obtained following 
drug administration during the day. The apparent 
blood CyA clearance was higher following drug ad-
ministration at night as compared with the clear-
ance obtained following daytime drug administra-
tion in both subjects. Patient 2 was studied on a 
third occasion (day 5 postoperatively), during the 
day. and was found to clear the drug in a pattern 
similar to that observed previously. Other pharma-
cokinetic parameters, such as the elimination rate 
constant and volume of distribution, could not be 
calculated because of the short dosing interval em-
ployed in treating these patients. 
In both the subjects studied, the clearance of 
CyA was higher during the night as compared with 
the clearance during the day. This phenomenon 
cannot be attributed to any variation in the ana-
lytical methodology, as our analytical procedure is 
highly reproducible. The coefficient of variation at 
600 ng/ml is 3.4% (n = 6). The intrapatient vari-
ability in CyA kinetics cannot account for the ob-
served differences in CyA kinetics, as demon-
strated by the data obtained from Patient 2. During 
the study period, the patients did not receive any 
drugs known to induce or inhibit drug-metabolizing 
enzymes. The presence of circadian rhythms in 
various biological systems has long been recog-
nized. Recently, diurnal variations in the pharma-
cokinetics of theophylline (11), valproic acid (12), 
prednisolone (13), and ethanol (14) have been re-
ported. The actual mechanism(s) responsible for 
the observed diurnal variation in Cy A kinetics is 
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TABLE 1. Pharmacokinetics of cyclosporine in !il'er transplant patients 
Day post- Time of 
Subject transplant study 
21 2 p.m.-10 p.m. 
18 10 p.m.-6 a.m. 
2 3 10 a.m.-6 p.m. 
3 8 p.m.-4 a.m. 
5 9 a.m.-5 p.m. 
CyA, cyclosporine. 
not clear at this point. It may be related either to (a) 
circadian variations in the activities of one or more 
hepatic drug-metabolizing enzymes, as CyA is me-
tabolized to a significant extent by the liver in 
humans (15) or to (b) possible diurnal changes in 
plasma lipoprotein profiles, as Cy A is primarily 
transported by lipoproteins. Regardless of the 
mechanism involved in the diurnal variation ob-
served in the kinetics of Cy A, it is essential to stan-
dardize the time of blood sampling for accurate 
Cy A blood level monitoring. 
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